This is to inform you that Outcome of the Board Meeting of the Company held on today i.e. Tuesday 5th May, 2026 in accordance with SEBl (Listing Obligations and Disclosures Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Amerise Biosciences reported audited standalone financial results for FY2025-26 with total income of Rs. 25.52 lakhs, up 35.7% from Rs. 18.80 lakhs in the previous year. Net profit after tax stood at Rs. 1.61 lakhs, a significant improvement from Rs. 0.57 lakhs in FY2024-25, representing growth of over 180%. The company achieved this profit improvement despite a sharp rise in other expenses (Rs. 16.09 lakhs vs Rs. 7.86 lakhs). Total assets decreased to Rs. 742.19 lakhs from Rs. 846.33 lakhs, while shareholder funds marginally increased to Rs. 539.59 lakhs. The statutory auditors issued an Unmodified Opinion (clean audit report), confirming true and fair view of the financial statements. Other equity remains negative at Rs. 121.10 lakhs, indicating accumulated losses.
The company returned to profitability with strong bottom-line growth, which is positive for shareholders. However, the clean audit with unmodified opinion removes any audit-related concerns, and the modest EPS of Rs. 0.02 reflects the small scale of operations. Investors should note the company's minimal revenue base relative to its asset size.